Building The Worm Atlas For I&I Breakthroughs

10 Apr 2025

• By Ian Taylor

The next big thing in auto-immune therapies: worms. Or so a young California biotech believes. Holoclara is pioneering a new class of medicines derived from intestinal worms to revolutionize the treatment of autoimmune diseases, allergies, and more.

Key Takeaways

Holoclara is developing therapeutics from worm secretions, aiming to modulate the immune system rather than suppress it.
The company is conducting a Phase I clinical trial for HC002, a worm-derived small molecule targeting eosinophilic esophagitis, with promising implications for broader immunology and inflammation treatments.
Holoclara's proprietary discovery engine and 'worm atlas' could lead to a new class of medicines, addressing various clinical concerns and potentially transforming patient care.

As Eureka moments go, Andrea Choe’s was very 21st century. Choe is the CEO and co-founder of Holoclara, a biotech start-up investigating a new class of medicines derived from intestinal...

“Someone sent me this podcast about a guy who goes to Africa and walks around barefoot trying to get hookworms, on purpose, to treat his untreatable asthma,” Choe told In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Leaders At The Frontier: Conversations From SynBioBeta 2025

26 May 2025

• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.

From IVF Failure To Fertility Breakthroughs: Freya’s Microbiome Mission

26 May 2025

• By Jo Shorthouse

Named after the Norse goddess of fertility, Freya Biosciences is mapping the reproductive microbiome with a host of women's health indications as the final destination.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

21 May 2025

• By Anabel Costa-Ferreira

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

20 May 2025

• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

20 May 2025

• By David Wild

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.